James Fettiplace

519 total citations
20 papers, 387 citations indexed

About

James Fettiplace is a scholar working on Rheumatology, Immunology and Hepatology. According to data from OpenAlex, James Fettiplace has authored 20 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 6 papers in Immunology and 6 papers in Hepatology. Recurrent topics in James Fettiplace's work include Systemic Lupus Erythematosus Research (8 papers), Liver Diseases and Immunity (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). James Fettiplace is often cited by papers focused on Systemic Lupus Erythematosus Research (8 papers), Liver Diseases and Immunity (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). James Fettiplace collaborates with scholars based in United States, United Kingdom and India. James Fettiplace's co-authors include David A. Roth, Richard Furie, Cynthia Aranow, Daniel J. Wallace, Ronald van Vollenhoven, Beulah Ji, Amy Heath, David Gordon, Winn Chatham and David Gordon and has published in prestigious journals such as Journal of Hepatology, Annals of the Rheumatic Diseases and The American Journal of Gastroenterology.

In The Last Decade

James Fettiplace

18 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Fettiplace United States 8 304 251 169 39 36 20 387
Myron Chu United States 9 330 1.1× 252 1.0× 191 1.1× 44 1.1× 22 0.6× 14 395
Benjamin Empson United Kingdom 2 204 0.7× 113 0.5× 61 0.4× 35 0.9× 23 0.6× 2 267
Yong‐Wook Park South Korea 10 231 0.8× 251 1.0× 36 0.2× 45 1.2× 11 0.3× 13 445
Johanna MW Hazes Netherlands 10 155 0.5× 203 0.8× 175 1.0× 20 0.5× 23 0.6× 11 421
Davide Gianfreda Italy 8 262 0.9× 119 0.5× 41 0.2× 38 1.0× 26 0.7× 12 369
Simrat Randhawa United States 6 362 1.2× 160 0.6× 95 0.6× 30 0.8× 10 0.3× 13 424
Francesco Natalucci Italy 9 246 0.8× 98 0.4× 51 0.3× 36 0.9× 9 0.3× 40 304
Evan S. Vista United States 11 201 0.7× 136 0.5× 42 0.2× 29 0.7× 9 0.3× 13 311
Michelle Petri United States 2 301 1.0× 189 0.8× 36 0.2× 43 1.1× 9 0.3× 3 328
S Toloza United States 7 395 1.3× 292 1.2× 55 0.3× 66 1.7× 6 0.2× 8 456

Countries citing papers authored by James Fettiplace

Since Specialization
Citations

This map shows the geographic impact of James Fettiplace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Fettiplace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Fettiplace more than expected).

Fields of papers citing papers by James Fettiplace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Fettiplace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Fettiplace. The network helps show where James Fettiplace may publish in the future.

Co-authorship network of co-authors of James Fettiplace

This figure shows the co-authorship network connecting the top 25 collaborators of James Fettiplace. A scholar is included among the top collaborators of James Fettiplace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Fettiplace. James Fettiplace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Smith, Helen T., James Fettiplace, Robyn von Maltzahn, et al.. (2025). Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study. Hepatology Communications. 9(3). 3 indexed citations
3.
Langford, R. M., Esther Pogatzki‐Zahn, Adelaida Morte, et al.. (2024). Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1). Advances in Therapy. 41(3). 1025–1045. 8 indexed citations
4.
Karatza, Eleni, Brandon Swift, F. Carreño, et al.. (2024). Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat. Liver International. 44(9). 2293–2302. 5 indexed citations
5.
6.
Langford, R. M., Adelaida Morte, Mariano Sust, et al.. (2022). Efficacy and safety of co‐crystal of tramadol‐celecoxib (CTC) in acute moderate‐to‐severe pain after abdominal hysterectomy: A randomized, double‐blind, phase 3 trial (STARDOM2). European Journal of Pain. 26(10). 2083–2096. 13 indexed citations
7.
Fettiplace, James, Brandon Swift, Shu Zhang, Robyn von Maltzahn, & Megan McLaughlin. (2022). Investigation of linerixibat 40mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the phase 2b GLIMMER study to support the phase 3 GLISTEN study. Journal of Hepatology. 77. S335–S336. 1 indexed citations
8.
Smith, Helen, et al.. (2022). More than just an itch: impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL). Journal of Hepatology. 77. S327–S328. 3 indexed citations
9.
Smith, Helen T., et al.. (2022). S107 More Than Just an Itch: Impact of Cholestatic Pruritus in Primary Biliary Cholangitis (PBC) on Health-Related Quality of Life (HRQoL). The American Journal of Gastroenterology. 117(10S). e77–e78. 1 indexed citations
10.
Sadik, Christian D., Hanan Rashid, Christoph M. Hammers, et al.. (2022). Evaluation of Nomacopan for Treatment of Bullous Pemphigoid. JAMA Dermatology. 158(6). 641–641. 26 indexed citations
11.
Nunn, Miles A. & James Fettiplace. (2021). 25178 Disease remission during a short-term treatment phase II study of nomacopan in mild-to-moderate bullous pemphigoid. Journal of the American Academy of Dermatology. 85(3). AB54–AB54. 3 indexed citations
12.
Wallace, Daniel J., Ellen M. Ginzler, Joan T. Merrill, et al.. (2019). Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 71(7). 1125–1134. 84 indexed citations
13.
Vollenhoven, Ronald van, Sandra Navarra, Roger A. Levy, et al.. (2019). Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Lara D. Veeken. 59(2). 281–291. 64 indexed citations
14.
Furie, Richard, Daniel J. Wallace, Cynthia Aranow, et al.. (2018). Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 70(6). 868–877. 68 indexed citations
15.
Vollenhoven, Ronald van, Sandra Navarra, Roger A. Levy, et al.. (2018). OP0252 Organ damage progression and long-term safety of belimumab (BEL) in patients with systemic lupus erythematosus (SLE): an extension of pivotal phase 3 bliss studies. Annals of the Rheumatic Diseases. 77. 175–176. 1 indexed citations
16.
Wallace, DJ, EM Ginzler, JT Merrill, et al.. (2017). OP0232 Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE. Annals of the Rheumatic Diseases. 76. 150–151. 5 indexed citations
17.
18.
Bruce, Ian N, Murray B. Urowitz, Ronald van Vollenhoven, et al.. (2016). Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 25(7). 699–709. 67 indexed citations
19.
Fettiplace, James, Beulah Ji, & David A. Roth. (2016). THU0231 Belimumab in Paediatric SLE (The PLUTO Study) – Study Design and Participation. Annals of the Rheumatic Diseases. 75. 271–272. 2 indexed citations
20.
Bruce, Ian N, Murray B. Urowitz, Ronald van Vollenhoven, et al.. (2015). OP0186 5-Year Organ Damage Accrual and Safety in Patients with Sle Treated with Belimumab Plus Standard of Care. Annals of the Rheumatic Diseases. 74. 142–142. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Myron Chu Breakdown of academic impact, for papers by Benjamin Empson Breakdown of academic impact, for papers by Yong‐Wook Park Breakdown of academic impact, for papers by Johanna MW Hazes Breakdown of academic impact, for papers by Davide Gianfreda Breakdown of academic impact, for papers by Simrat Randhawa Breakdown of academic impact, for papers by Francesco Natalucci Breakdown of academic impact, for papers by Evan S. Vista Breakdown of academic impact, for papers by Michelle Petri Breakdown of academic impact, for papers by S Toloza
Rankless by CCL
2026